31.2 C
New York
Thursday, July 3, 2025

Tag: MRI

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...

Oncology Innovation Just Hit a Turning Point — Here’s What to Watch

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape...

HealthpointCapital Acquires ImmersiveTouch, Inc., a Leading Extended Reality Surgical Platform

SAN DIEGO and CHICAGO, June 30, 2025 /PRNewswire/ -- HealthpointCapital, the leading private equity firm focused exclusively on musculoskeletal healthcare, today announced the acquisition...

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

−  Results show delivery of high radiation doses to tumours compared with normal organs.−  Observed normal organ absorbed dosimetry results may allow administration of...

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

−  Results show delivery of high radiation doses to tumours compared with normal organs.−  Observed normal organ absorbed dosimetry results may allow administration of...

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression

Aetna Supports Industry Actions to Simplify Prior Authorization

Company commits to distinctive actions that will make it easier to navigate the health care system, access care, and achieve better healthHARTFORD, Conn., June...

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal...


Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91 for identification and treatment of patients who have unresectable, locally advanced or metastatic solid tumors. As a new component of a broad clinical development plan for ITM-91/ITM-94, Part D of the trial will evaluate the effectiveness of ITM-94 in classifying indeterminate renal mass as either ccRCC or non-cancerous.

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy...

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development,...

Over $7.7M in Ontario-Based Platforms to Advance Open Science and Brain Health Innovation

Two cutting-edge platforms at CAMH and Western University aim to accelerate AI-driven brain research and global data sharing TORONTO, June 20, 2025 /CNW/ - Brain Canada...

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors –

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy

Professors Shiv Saidha, Cristina Granziera, David Leppert, and Roberto Furlan are world-renowned experts in neuroimaging, multiple sclerosis (MS) biomarkers, neuroimmunology, and translational drug developmentAppointments...

Human Longevity, Inc. Expands Pancreatic Cancer Prevention Commitment with $1 Million Pledge for Qualified Members

SOUTH SAN FRANCISCO, Calif., June 17, 2025 /PRNewswire/ -- Human Longevity, Inc. (HLI), a global leader in precision medicine and proactive health, today announced...

FOX NEWS CHANNEL’S BRET BAIER LANDS FIRST INTERVIEW WITH ISRAELI PRIME MINISTER BENJAMIN NETANYAHU SINCE ISRAEL’S STRIKES ON IRAN ON SUNDAY, JUNE 15TH

NEW YORK, June 14, 2025 /PRNewswire/ -- FOX News Channel's Bret Baier will present a worldwide exclusive live interview with Israeli Prime Minister Bibi Netanyahu on...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMRI